RightFit
Not yet recruitingPhase not listed

Obstructive Sleep Apnea as a Risk Factor for Normal Tension Glaucoma and a Crucial Step in Preventing Blindness

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
21 Years and older
Sex
All sexes
Healthy volunteers
Not stated
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study looks at the link between obstructive sleep apnea, which causes pauses in breathing during sleep, and glaucoma with normal eye pressure. It tests whether sleep apnea treatment improves blood vessel health in the retina, the light-sensing layer at the back of the eye, and early signs of vision problems. It is for adults newly diagnosed with sleep apnea who will start CPAP treatment.

The purpose of this research study is to learn more about the relationship between Obstructive Sleep Apnea (OSA) and Normal Tension Glaucoma (NTG). OSA is a nighttime disorder of the upper airway that causes an intermittent lack of oxygen while sleeping. NTG is a type of glaucoma that occurs despite the normal intraocular pressure levels, making its detection more difficult. Left untreated, irreversible optic nerve damage and extensive vision loss can result. Previous research has shown some evidence between OSA and the development of NTG. The investigators are researching whether undergoing treatment for OSA would help to improve the vascular health to the retina, and in effect, improve the early signs of visual dysfunction seen with diagnostic testing.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You have newly diagnosed obstructive sleep apnea and will start CPAP, a treatment that uses air pressure to keep your airway open during sleep.
  • You are at least 21 years old.
  • Your vision with glasses or contacts is 20/40 or better. Your prescription must meet the listed limits: spherical power less than ±6.0 diopters and cylinder power less than -3.0 diopters. These numbers measure the lens strength you need.
  • You can follow instructions and plan to attend all study visits.

Who can't join

  • Your glasses or contact lens prescription is outside the study limits, listed as spherical power greater than ±6.0 diopters and cylinder power greater than -3.0 diopters.
  • You have narrow-angle glaucoma, a type of glaucoma with a narrow drainage space inside the eye.
  • You have had a severe eye injury, inflammation inside the eye, or surgery inside the eye. Cataract surgery without complications is allowed if an artificial lens was placed behind the iris, the colored part of the eye.
  • You have a health or eye condition that makes participation unsuitable. Examples include eye damage from diabetes or other changes in the retina that prevent a reliable check of the optic nerve, which carries signals from the eye to the brain.
  • You are allergic or very sensitive to any ingredient in Altafluor Benox.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Newly diagnosed subjects with OSA that will undergo CPAP treatment. * At least 21 years of age * Best corrected vision of 20/40 or better, spherical Rx \< ± 6.0 Diopter, and cylinder \<-3.0D * Ability to follow instructions, and intent to complete all study visits Exclusion Criteria: * High Rx \>± 6.0D and cylinder \> -3.0D * Narrow angle glaucoma * History of any of the following: severe eye trauma, ocular inflammation, previous intraocular surgery except for uncomplicated cataract extraction with posterior chamber intraocular lens implantation. * Any medical or ocular condition which is not appropriate for participation in the trial (Diabetic retinopathy, and other retinal changes preventing reliable optic disc evaluation) Hypersensitivity to any component of altafluor benox

Study sites (2)

NY